Share of the pharma major fell about 4 per cent in the first one hour of the trade on Friday. Experts see concerns over the US business, as well as, pressure on operating performance as key drags. Despite near-term headwinds, most brokerage firms maintained their rating and target prices but slashed earnings per share (EPS) estimates for FY23-24.
Kusumgar IPO Day 3: Issue ends subscription with 129x bids; GMP signals 38% listing upside
Kusumgar’s Rs 650-crore IPO concluded with overwhelming investor demand on its final day. Non-Institutional Investors and Qualified Institutional Buyers showed significant interest in the offering.
July 10, 2026